STAT
JULY 25, 2024
UnitedHealth Group started out as a small, Minnesota health insurance company and has since morphed into a modern-day Standard Oil, exerting unmatched dominance over health care in the United States. It’s no secret that UnitedHealth is a colossus: It’s the country’s largest health insurer and the fourth-largest company of any type by revenue, just behind Apple.
BioPharma Dive
JULY 18, 2024
The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 23, 2024
Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and active pharmaceutical ingredients (APIs).It's a statement of intent from Agilent, whose primary business is lab instrumentation and equipment, suggesting that it intends to grow the outsourcing side of its business, which is currently focused on the production of oligonucleotide and peptide medicines.
Pharma Times
JULY 24, 2024
The neurodegenerative disease is currently the most common cause of dementia
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Express Pharma
JULY 25, 2024
NewAmsterdam Pharma has completed the enrollment of 407 patients in the pivotal Phase III TANDEM clinical trial evaluating obicetrapib in combination with ezetimibe in patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD). Obicetrapib has demonstrated strong tolerability in more than 800 patients with elevated lipid levels in NewAmsterdam’s clinical trials to date.
The Pharmacist
JULY 16, 2024
Community pharmacies in south-east London have launched what is believed to be England’s only nationally-funded inhaler recycling pilot. NHS England (NHSE) has funded the scheme, which aims to reduce greenhouse gases from metered dose inhalers. Patients will be encouraged to return their used or expired inhalers to one of 20 participating community pharmacies.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
BioPharma Dive
JULY 15, 2024
Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
pharmaphorum
JULY 11, 2024
The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the prices of medicines in the US.
The Guardian - Pharmaceutical Industry
JULY 23, 2024
Generic version of a drug already on the market, which can suppress and prevent HIV, would still yield 30% profit if the current price was slashed, researchers say A new drug described as “the closest we have ever been to an HIV vaccine” could cost $40 (£31) a year for every patient, a thousand times less than its current price, new research suggests.
Express Pharma
JULY 24, 2024
Kiran Mazumdar Shaw, Chairperson, Biocon & Biocon Biologics “The Union Budget for FY25 builds further on the government’s pre-election, Interim Budget and has positive indicators on how the government is looking at India’s economic growth and development. The FM’s emphasis on job creation through skilling is a key underlying theme. Internships at large companies with Government and CSR-backed stipends are the right approach to employability and jobs for the future.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The Pharmacist
JULY 23, 2024
Primary care network (PCN) pharmacists should be enabled to prioritise structured medication reviews (SMRs) in the highest risk patients, the Royal Pharmaceutical Society (RPS) has said in a policy statement today. This follows concerns that PCNs and practices are deprioritising SMRs and directing pharmacists towards other work. RPS England vice-chair Brendon Jiang suggested that the […] The post Pharmacists must be enabled to prioritise SMRs, urges RPS appeared first on The Pharmacist.
STAT
JULY 23, 2024
Jeffrey Shuren, longtime chief regulator of medical devices at the Food and Drug Administration, announced to staff on Tuesday that he is leaving the agency, according to six sources and an email reviewed by STAT. Shuren, who spent 28 years at the agency, started his FDA career in the Commissioner’s Office in 1998. He became director of the Center for Devices and Radiological Health in 2009 and has served in that position ever since.
BioPharma Dive
JULY 22, 2024
The company plans to start a late-stage study next year, after a smaller trial found its drug offered “robust and consistent” benefits on communication, cognition and motor function.
pharmaphorum
JULY 24, 2024
The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them of monopolising the supply chain.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmaTech
JULY 17, 2024
The company has issued a voluntary recall of one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV), because of incorrect strength published on product carton.
Express Pharma
JULY 6, 2024
The hemp industry in India is expanding rapidly, but there are several obstacles standing in its way. These include strict rules and regulations and a lot of misinformation. The sector can only flourish if the government provides backing in the form of legalisation and awareness campaigns on hemp and its products. Focusing on sustainable development and a defined course of action will establish India as a leader in the global hemp market and encourage ethical practices.
Pharmaceutical Technology
JULY 1, 2024
On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.
STAT
JULY 23, 2024
Medicare and Medicaid are facing a familiar quandary: how to provide coverage for new weight loss drugs with price tags that could effectively bankrupt the federal government’s health care budget while simultaneously ensuring continuous coverage for all other health care services used by millions of Americans. The Centers for Medicare and Medicaid Services announced in March 2024 that it would cover Wegovy (semaglutide), a new and expensive weight loss medication, for beneficiaries with c
BioPharma Dive
JULY 1, 2024
Study results are expected for a pair of closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.
pharmaphorum
JULY 25, 2024
Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.
Pharma Times
JULY 9, 2024
Myricx Bio’s therapies include treatments for breast, lung and colorectal cancer
Express Pharma
JULY 23, 2024
“The Union Budget 2024-25, presented by FM Nirmala Sitharaman, marks a significant milestone as the first budget of the re-elected BJP-led NDA government. We at OPPI commend the government’s commitment to improving healthcare access and innovation in India, reflecting a forward-looking approach that aligns with our industry’s aspirations. We deeply appreciate the government’s decision to exempt three critical cancer medicines – Trastuzumab Deruxtecan, Osimertinib, and Durvalumab – fr
Pharmaceutical Technology
JULY 22, 2024
As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.
STAT
JULY 22, 2024
Express Scripts, one of the largest pharmacy benefit managers in the country, overcharged U.S. Postal Service employees by a whopping $45 million for their prescription drugs during a recent five-year period, according to a federal audit. The findings are likely to intensify scrutiny of the controversial role played by PBMs in the opaque pharmaceutical pricing system.
BioPharma Dive
JULY 11, 2024
Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.
pharmaphorum
JULY 12, 2024
A new payment policy proposal released by the Centers for Medicare and Medicaid Services (CMS) this week covers digital tools used for behavioural health, which could be a boost for the digital health sector.The Medicare Physician Fee Schedule (PFS) sets out the method of payment, rates, and codes for healthcare providers participating in Medicare, and is often used by the administration as an instrument to encourage some forms of healthcare intervention.
Pharma Times
JULY 5, 2024
The neurodegenerative disease currently affects more than 200,000 people worldwide
Express Pharma
JULY 22, 2024
SynaptixBio, a company licensed to commercialise a treatment for a rare, incurable and deadly disease, has announced its collaboration with Evotec, to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy. Drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research, under a sponsored research agreement.
Drug Patent Watch
JULY 24, 2024
In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility.
STAT
JULY 23, 2024
Following the release of widely touted study results for a Gilead Sciences HIV treatment, a new analysis finds the medicine — called lenacapavir — could be made for as little as $26 to $40 per person each year, which the researchers argue could alleviate concerns about limited access in many countries. The medicine drew considerable attention last month after a late-stage clinical trial found that twice-a-year injections completely protected cisgender women from contracting HIV.
BioPharma Dive
JULY 2, 2024
The company claimed Phase 2 study results prove the therapy’s promise treating myasthenia gravis. But shares lost more than a quarter of their value amid questions about the data.
pharmaphorum
JULY 10, 2024
Learn how to successfully transition pilots into production with GenAI in the pharmaceutical industry. Discover strategies to create, scale, and achieve success with this innovative technology.
Pharmaceutical Technology
JULY 15, 2024
AstraZeneca has obtained Health Canada’s Notice of Compliance (NOC) for Tagrisso (osimertinib) to treat NSCLC.
Express Pharma
JULY 23, 2024
Gland Pharma a generic injectable-focused pharmaceutical company, has received tentative approval from the United States Food and Drug Administration (USFDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024 per cent. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyzulta Ophthalmic Solution, 0.024 per cent, registered by Bausch & Lomb.
Expert insights. Personalized for you.
363 
Let's personalize your content